Tetrahydrocannabivarin (THCV) Research Dashboard
Studies by Organ System
No data to display
Studies by Country of Researcher
No data to display
Top Conditions Related to THCV Studies
No data to display
Receptors Associated with THCV Studies
No data to display
THCV Has Shown Proven Effects in Clinical Human Trials for these conditions:
Page Quick Links
Select New Cannabinoid
38 PRIMARY STUDIES | 49 TOTAL STUDIES
Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots
Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
Development and Optimization of Supercritical Fluid Extraction Setup Leading to Quantification of 11 Cannabinoids Derived from Medicinal Cannabis
Fast liquid chromatography-tandem mass spectrometry method for the simultaneous determination of phytocannabinoids in oily based preparations
Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms
Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target
Identification and quantification of cannabinoids in postmortem fluids and tissues by liquid chromatography-tandem mass spectrometry
An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models
Screening and confirmation methods for the qualitative identification of nine phytocannabinoids in urine by LC-MS/MS
The Cannabinoids Tetrahydrocannabinol, Cannabinol, Cannabidiol, Tetrahydrocannabivarin, and 11-nor-9-carboxy-∆9-THC in Hair
Quantitation of Δ8-THC, Δ9-THC, Cannabidiol, and Ten Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS/MS
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L
Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes
High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain
Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath
Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets
Cannabinoids and Cannabinoid Receptors: The Story so Far
Synthesis of the Major Mammalian Metabolites of THCV
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence
Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats
Δ8-Tetrahydrocannabivarin Prevents Hepatic Ischaemia/Reperfusion Injury by Decreasing Oxidative Stress and Inflammatory Responses Through Cannabinoid CB2 Receptors
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo
11 RELATED STUDIES | 49 TOTAL STUDIES
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
Future Aspects for Cannabinoids in Breast Cancer Therapy
Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients
Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome
Molecular Targets of the Phytocannabinoids-A Complex Picture
Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth In Vitro And In Vivo: Pro-apoptotic Effects And Underlying Mechanisms
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Overview - Tetrahydrocannabivarin (THCV)
Description of Tetrahydrocannabivarin (THCV)
Δ9-Tetrahydrocannabivarin (THCV) was discovered in 1971. [Δ(8) -THCV (is a synthetic analogue of the plant cannabinoid Δ(9) -THCV]. THCV belongs to the THC group but produces different effects than THC. A lot of attention is given THCV of late due to the observation that it may be able to produce therapeutic effects in obesity related diabetes especially in contrast to the failed approach with Rimonabant, the CB1 inverse agonist used to treat obesity but then pulled from market due to the potential increased of mood disorders.Other Names:
Delta 9-TetrahydrocannabivarinTetrahydrocannabivarin (THCV) Properties and Effects
THCV modulates lipid and sugar metabolism (i.e. reduces insulin sensitivity) and as such THCV may represent a novel therapeutic agent to induce glycemic control in patients with type 2 diabetes; antioxidant and neuroprotective [i.e. reduces symptoms in an animal model of Parkinson's disease (i.e. reduces L-DOPA-induced dyskinesia)]; antimicrobial (i.e. against MRSA); THCV inhibited some effects of THC (e.g. reduced THC associated increases in heart rate, decrease in THC associated psychoactivity) while increasing others i.e. significantly increased memory intrusions; THCV may induce dose dependent dysphoria (due to its antagonistic effects at CB1); Δ8 -THCV may have potential anti-nicotine effects.Tetrahydrocannabivarin (THCV) Receptor Binding
Pooling five studies THCV has a reported Ki of 64.2 ± 14.14 nM (McPartland, Pertwee et. al. 2015); THCV is considered a tissue specific and dose-dependent (low dose) antagonist at CB1 receptors (high dose agonist); data further suggests THCV's ability to modulate CB2 (partial agonist), GPR-55, and Serotonin receptor sites (5-HT1A).Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.